Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2019 Jan 10

PMID 30623310

Citations 17

Authors

Mark Dominic Latt

Simon Lewis

Olfat Zekry

Victor S C Fung

Affiliations

Soon will be listed here.

Abstract

Dopamine agonists (DAs) are frequently used in the management of Parkinson's disease (PD), a complex multisystem disorder influenced substantially by age-related factors. Over 80% of PD patients present after age 60 years and may have clinical features exacerbated by age-related comorbidities or decline in physiological compensatory mechanisms. Pharmacotherapy for motor symptoms in older persons is more likely to involve exclusive use of levodopa combined with a peripheral decarboxylase inhibitor throughout the course of the illness. Non-ergot DAs, such as pramipexole, rotigotine and ropinirole, may be used as de novo monotherapy for the control of motor symptoms in older persons, although they are less efficacious than levodopa therapy. DAs may also be considered as adjunct therapy in older persons when motor symptoms are no longer adequately controlled by levodopa or when motor fluctuations and dyskinesia appear. DAs may be used cautiously in older persons with cognitive impairment and orthostatic hypotension but should be avoided when there is a history or risk of psychosis or impulse control disorders.

Citing Articles

Lipid-based nanoparticles for drug delivery in Parkinson's disease.

Cai H, Liu D, Xue W, Ma L, Xie H, Ning K Transl Neurosci. 2024; 15(1):20220359.

PMID: 39654878 PMC: 11627081. DOI: 10.1515/tnsci-2022-0359.

Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.

Isaacson S, Hauser R, Pahwa R, Gray D, Duvvuri S Clin Park Relat Disord. 2023; 9:100212.

PMID: 37497384 PMC: 10366643. DOI: 10.1016/j.prdoa.2023.100212.

Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson's disease.

Su D, Zhang X, Su Y, Chan P, Xu E Heliyon. 2023; 9(7):e17876.

PMID: 37483692 PMC: 10362309. DOI: 10.1016/j.heliyon.2023.e17876.

Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach.

Baweja G, Gupta S, Kumar B, Patel P, Asati V Mol Divers. 2023; 28(3):1823-1845.

PMID: 36977955 PMC: 10047469. DOI: 10.1007/s11030-023-10634-6.

Relationship Between Gut Bacteria and Levodopa Metabolism.

Xu K, Sheng S, Zhang F Curr Neuropharmacol. 2022; 21(7):1536-1547.

PMID: 36278467 PMC: 10472813. DOI: 10.2174/1570159X21666221019115716.

References

Jenner P . Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. 2002; 58(4 Suppl 1):S1-8. DOI: 10.1212/wnl.58.suppl_1.s1. View

Sauerbier A, Jenner P, Todorova A, Chaudhuri K . Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S41-6. DOI: 10.1016/j.parkreldis.2015.09.027. View

Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F . Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015; 21(3):199-204. DOI: 10.1016/j.parkreldis.2014.11.024. View

Hely M, Morris J, Reid W, Trafficante R . Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2004; 20(2):190-9. DOI: 10.1002/mds.20324. View

Stowe R, Ives N, Clarke C, Deane K, Wheatley K, Gray R . Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010; (7):CD007166. DOI: 10.1002/14651858.CD007166.pub2. View

Cruse B, Morales-Briceno H, Chang F, Mahant N, Ha A, Kim S . 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease. NPJ Parkinsons Dis. 2018; 4:34. PMC: 6243994. DOI: 10.1038/s41531-018-0070-4. View

Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P . Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci. 2008; 35(2):173-8. DOI: 10.1017/s0317167100008593. View

Kebabian J, Calne D . Multiple receptors for dopamine. Nature. 1979; 277(5692):93-6. DOI: 10.1038/277093a0. View

. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View

10.

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

11.

Camilleri M, Parkman H, Shafi M, Abell T, Gerson L . Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2012; 108(1):18-37. PMC: 3722580. DOI: 10.1038/ajg.2012.373. View

12.

Glare P, Miller J, Nikolova T, Tickoo R . Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011; 6:243-59. PMC: 3180521. DOI: 10.2147/CIA.S13109. View

13.

Abassi Z, Binah O, Youdim M . Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004; 143(3):371-8. PMC: 1575354. DOI: 10.1038/sj.bjp.0705962. View

14.

Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B . Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord. 2012; 19(1):37-42. DOI: 10.1016/j.parkreldis.2012.06.009. View

15.

Alvir J, Lieberman J, Safferman A, Schwimmer J, Schaaf J . Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329(3):162-7. DOI: 10.1056/NEJM199307153290303. View

16.

Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I . Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002; 17(1):188-91. DOI: 10.1002/mds.1276. View

17.

Kaye C, Nicholls B . Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000; 39(4):243-54. DOI: 10.2165/00003088-200039040-00001. View

18.

Holloway R, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K . Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004; 61(7):1044-53. DOI: 10.1001/archneur.61.7.1044. View

19.

Levy G . The relationship of Parkinson disease with aging. Arch Neurol. 2007; 64(9):1242-6. DOI: 10.1001/archneur.64.9.1242. View

20.

Antonini A, Fung V, Boyd J, Slevin J, Hall C, Chatamra K . Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord. 2016; 31(4):530-7. PMC: 5066747. DOI: 10.1002/mds.26528. View